TrialA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Trial details
- Registry ID
- NCT04395677
- Phase
- Phase 2
NUVB
Nuvation Bio Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
6Trials in this database
19Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneNCT04395677 | NUVB | Phase 2 | Active not recruiting | 2024-06-07Actual |
| Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionNCT04617054 | NUVB | Phase 2 | Terminated | 2024-12-06Actual |
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNCT04919811 | NUVB | Phase 2 | Active not recruiting | 2025-06-11Actual |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519 | NUVB | Phase 3 | Recruiting | 2028-12-01Estimated |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsNCT06564324 | NUVB | Phase 3 | Recruiting | 2029-01Estimated |
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706 | NUVB | Phase 3 | Recruiting | 2030-08-30Estimated |
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Trial details
- Registry ID
- NCT04617054
- Phase
- Phase 2
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Trial details
- Registry ID
- NCT04919811
- Phase
- Phase 2
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Trial details
- Registry ID
- NCT05303519
- Phase
- Phase 3
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Trial details
- Registry ID
- NCT06564324
- Phase
- Phase 3
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Trial details
- Registry ID
- NCT07154706
- Phase
- Phase 3
Latest recorded trial changes
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324 · Nuvation Bio Inc.
Planned enrollment increased by 56 participants
− Before
138 participants (planned)
+ After
194 participants (planned)
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
NCT04395677 · Nuvation Bio Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
30 Dec 2023
+ After
7 Jun 2024
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519 · Nuvation Bio Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0
+ After
Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 Measure: Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0
Planned enrollment increased by 240 participants
− Before
125 participants (planned)
+ After
365 participants (planned)
Primary completion date changed
− Before
1 Dec 2027
+ After
1 Dec 2028
Phase changed
− Before
PHASE2
+ After
PHASE3
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
NCT04617054 · Nuvation Bio Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Best overall response (BOR)
+ After
Measure: Objective response rate (ORR)
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
40 participants (planned)
+ After
14 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
30 Apr 2024
+ After
6 Dec 2024
Recruitment status changed
− Before
Recruiting
+ After
Terminated
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811 · Nuvation Bio Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
224 participants (planned)
+ After
217 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Jun 2025
+ After
11 Jun 2025
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting